Bio-Gene Technology

Bio-Gene Technology Net Debt/Equity

The Net Debt to Equity Ratio of Bio-Gene Technology (BGT.AX) as of Oct 21, 2026 is -0.67. In the previous year, Net Debt to Equity Ratio was -0.79 — a change of -15.60% (higher).

Net Debt/Equity

-0.67

YoY

-15.60%

Last updated:

Net Debt to Equity Ratio of Bio-Gene Technology is 2025 -0.67 . Net Debt to Equity Ratio of Bio-Gene Technology was 2024 -0.79 . It decreases by -15.60% higher compared to the previous year.

The Bio-Gene Technology Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-0.95 AUD
Jan 1, 2019
-0.88 AUD
Jan 1, 2020
-0.89 AUD
Jan 1, 2021
-0.89 AUD
Jan 1, 2022
-1.01 AUD
Jan 1, 2023
-0.93 AUD
Jan 1, 2024
-0.79 AUD
Jan 1, 2025
-0.67 AUD
The Bio-Gene Technology Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.67-15.60%
-0.79-14.73%
-0.93-8.24%
-1.01+13.55%
-0.89-0.23%
-0.89+1.62%
-0.88-7.42%
-0.95-0.37%
-0.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology Ltd develops and commercializes insecticides using beta-triketone platform technology. The company's lead products are Flavocide, a chemically synthesized insecticide based on flavesone, and Qcide, a natural oil product containing tasmanone extracted from Gympie Messmate leaves via steam distillation. These products address insecticide resistance and toxicity issues in crop protection, storage, public health, animal health, and consumer applications. Insecticide manufacturers purchase the company's platform technology and products for commercialization across multiple sectors. The firm's beta-triketone platform provides multiple solutions for insecticide manufacturers seeking to develop novel pest control products. Flavocide and Qcide represent the company's primary commercial offerings, with Flavocide targeting synthetic insecticide markets and Qcide focusing on natural oil-based solutions. The company's technology enables the development of targeted insect control solutions for various applications including agricultural crop protection and public health management. Bio-Gene Technology Ltd. aims to develop a portfolio of targeted insect control solutions for insecticide manufacturers. The company's platform technology allows manufacturers to create new products addressing resistance and toxicity challenges. Through its two lead products, the company provides both synthetic and natural options for the insecticide market, targeting manufacturers who seek innovative solutions for pest management across different industry segments. Bio-Gene Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Gene Technology stock

Net Debt to Equity Ratio of Bio-Gene Technology is -0.67 in 2025.

Net Debt to Equity Ratio of Bio-Gene Technology changed from -0.79 to -0.67, representing a -15.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Bio-Gene Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio-Gene Technology

All Key Metrics — Bio-Gene Technology